We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Reports Positive Results From Phase 3 Pediatric Trial of Cosentyx
Novartis Reports Positive Results From Phase 3 Pediatric Trial of Cosentyx
Novartis said its top-selling drug Cosentyx (secukinumab) significantly delayed time to worsening of symptoms in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) in a late-stage study.